Vernalis Therapeutics, Inc. launched its first product in the US prescription market, Tuzistra® XR (codeine polistirex and chlorpheniramine polistirex) an extended-release CIII cough cold liquid. The Company also acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older.
Click here for further information about Tuzistra® XR.
Click here for full Prescribing Information for Moxatag®.
Click here for more information on our pipeline.